|
Abdominal Pain
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abdominal Pain
|
0.100 |
CausalMutation
|
phenotype |
CLINVAR |
|
|
|
|
Abnormal pigmentation of the oral mucosa
|
0.100 |
CausalMutation
|
phenotype |
CLINVAR |
|
|
|
|
Abnormal pigmentation of the oral mucosa
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of the ureter
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acinar Cell Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Recently, biallelic inactivation of LKB1 was described in an acinar cell carcinoma of a Peutz-Jeghers patient carrying a heterozygous germline LKB1 mutation, and inhibition of mTOR signaling resulted in partial remission of the tumor.
|
21572398 |
2011 |
|
Acinar cell carcinoma of pancreas
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma.
|
21572398 |
2011 |
|
Acute anaemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>miR-144/451</i> represses the LKB1/AMPK/mTOR pathway to promote red cell precursor survival during recovery from acute anemia.
|
29269522 |
2018 |
|
Acute GVH disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings reveal that Lkb1 downregulation contributes to multiple defects in Tregs in human aGVHD and highlight the Lkb1-related pathways that could serve as therapeutic targets that may potentially be manipulated to mitigate aGVHD.
|
31664223 |
2019 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunocytochemical staining showed that the expression of LKB1 was significantly decreased in adenocarcinoma and mucinous adenocarcinoma tissues, and this reduced expression induced the invasion and metastasis of CRC.
|
30483811 |
2019 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
|
12097271 |
2002 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
LKB1 modulates lung cancer differentiation and metastasis.
|
17676035 |
2007 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The inactivation of Stk11 in 27% (6/22) of IPMNs versus 7% (4/56) of pancreatic adenocarcinomas suggests genetic disparities in the pathogenesis of these closely related neoplasms.
|
12861065 |
2003 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
LKB1 modulates lung cancer differentiation and metastasis.
|
17676035 |
2007 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Taken together, our findings define new personalized therapeutic strategies that may be rapidly translated into clinical use for the treatment of KRAS/LKB1-mutant adenocarcinomas and squamous cell tumors.
|
26574479 |
2015 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Analysis of hamartomas and adenocarcinomas from patients with PJS identified loss of heterozygosity (LOH) of 19p markers near STK11 in 70% of tumors.
|
9850045 |
1998 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Somatic mutations of the STK11 gene were confirmed in 6 (55%) of the 11 mucinous MDAs and 1 (5%) of the 19 mucinous adenocarcinomas, but not in the 5 nonmucinous adenocarcinomas, the 15 squamous cell carcinomas, nor the 5 endocervical glands with gastric metaplasia.
|
12533684 |
2003 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Alterations characteristic of adenocarcinoma (EGFR, KRAS, ALK receptor tyrosine kinase [ALK], ROS1, and serine/threonine kinase 11 [STK11]) were detected in the LCC-AD subgroup but not in LCC-SqCC, whereas squamous-lineage alterations (phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha [PIK3CA], SRY-box 2 [SOX2], fibroblast growth factor receptor 1 [FGFR1], and AKT1) were detected in the LCC-SqCC subgroup but not in the LCC-AD group.
|
30978501 |
2019 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
APC:T1556fs and STK11 mutations found in duodenal adenomas/ACs highlight the importance of proteins encoded by these genes in tumor development.
|
29525853 |
2018 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis indicated that adenocarcinoma (P<0.05), lymph node metastasis (P<0.05), advanced TNM stage (P<0.001) and reduced expression of LKB1 (P<0.05) and Beclin1 (P<0.001) are all independent prognostic indicators for the survival of NSCLC patients.
|
25175672 |
2014 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Instead, concurrent mutations in TP53 and STK11 were shown to confer poor survival in the KRAS-positive adenocarcinoma subgroup.
|
30885352 |
2019 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The high level of cytoplasmic LKB1 expression was an independent risk factor for poor overall survival in patients with adenocarcinoma.
|
30033530 |
2018 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Acquired mutations in LKB1 are rarely observed in most sporadic tumor types except for adenocarcinomas of the lung where up to 50% harbor inactivating mutations.
|
16822578 |
2006 |